Skip to main content
Download PDF

The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study

Orphanet Journal of Rare Diseases volume 11, Article number: 12 (2016) Cite this article

Abstract

Background

There is no consensus in the literature regarding the impact of false positive newborn screening results on early health care utilization patterns. We evaluated the impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) in a cohort of Ontario infants.

Methods

The cohort included all children who received newborn screening in Ontario between April 1, 2006 and March 31, 2010. Newborn screening and diagnostic confirmation results were linked to province-wide health care administrative datasets covering physician visits, emergency department visits, and inpatient hospitalizations, to determine health service utilization from April 1, 2006 through March 31, 2012. Incidence rate ratios (IRRs) were used to compare those with false positive results for MCADD to those with negative newborn screening results, stratified by age at service use.

Results

We identified 43 infants with a false positive newborn screening result for MCADD during the study period. These infants experienced significantly higher rates of physician visits (IRR: 1.42) and hospitalizations (IRR: 2.32) in the first year of life relative to a screen negative cohort in adjusted analyses. Differences in health services use were not observed after the first year of life.

Conclusions

The higher use of some health services among false positive infants during the first year of life may be explained by a psychosocial impact of false positive results on parental perceptions of infant health, and/or by differences in underlying health status. Understanding the impact of false positive newborn screening results can help to inform newborn screening programs in designing support and education for families. This is particularly important as additional disorders are added to expanded screening panels, yielding important clinical benefits for affected children but also a higher frequency of false positive findings.

Background

Population-based newborn screening programs aim to pre-symptomatically identify newborns with treatable rare conditions. Many such programs throughout the world have expanded within the last decade [1], yielding important clinical benefits to affected children [2]. Despite high specificities associated with newborn screening tests, their positive predictive values are often relatively low due to the low birth prevalence of the screened diseases [3]. The expansion of newborn screening panels has consequently resulted in an overall increased number of false positive results.

Published evidence is inconsistent regarding the potential impact of false positive newborn screening results on parental psychosocial experiences [4–9]. Regarding health services use, some authors have observed higher rates of emergency department visits or hospitalizations among infants with false positive screening results, relative to screen-negative controls [7], yet others have found no significant differences [3–5], or differences only among preterm infants [10]. It is challenging to ascribe any increases in health services use to the parental psychosocial impact of receiving a false positive result. Infants born preterm or with low birth weight are more likely to receive positive newborn screening results in the absence of disease, due to their underlying biology and the nature of the biochemical markers used in the screening tests [10–12]. Abnormal values for such markers may also reflect other factors related to infant metabolism. Thus, increased health services use might be attributable to health needs rather than the screening result.

It has been hypothesized that false positive screening results for life-threatening illnesses such as medium-chain acyl-CoA dehydrogenase deficiency (MCADD) might provoke a stronger parental psychosocial response relative to other diseases [10]. MCADD is an inherited metabolic disease included on newborn screening panels in many jurisdictions [13, 14]. It affects the beta-oxidation pathway for medium-chain fatty acids, critical in times of physiological stress such as illness and fasting. Children diagnosed with MCADD have a hindered response to such stress [14, 15] and are susceptible to potentially fatal metabolic crises [16]. However, if early diagnosis is established, prognosis is excellent [14, 15, 17, 18].

Newborn Screening Ontario coordinates newborn bloodspot screening for approximately 140 000 babies born in Ontario, Canada each year. MCADD was added to the panel in April, 2006 [19]. All legal residents of Ontario are eligible for universal health insurance through the Ontario Health Insurance Plan (OHIP), encompassing a range of medically necessary services. At the Institute for Clinical Evaluative Sciences, encoded health care administrative data can be securely linked to newborn screening data with near complete population coverage [20, 21]; these data include information on gestational age and birth weight. This presents a unique opportunity to investigate the impact of a false positive newborn screening result while adjusting for important confounders. The objective of this study was to evaluate whether children who received false positive newborn screening results for MCADD experienced higher rates of health services use in early life relative to a screen negative cohort in Ontario.

Methods

This study was approved by the Ottawa Health Science Network Research Ethics Board, Protocol # 20120229-01H. Individual participant consent was not sought because the study involved the secondary use of population-wide health care administrative data.

Study population and data sources

Our source population included all children born in Ontario who received newborn screening between April 1, 2006 and March 31, 2010. The false positive cohort included children who received a positive newborn screening result for MCADD but were ultimately determined to be unaffected. In Ontario, screening for MCADD uses an algorithm involving C8 acylcarnitine (octanoylcarnitine) as a primary analyte, with C6 (hexanoylcarnitine), C10 (decanoylcarnitine), C10:1 (decenoylcarnitine), C8/C10 ratio, and C8/C2 ratio as secondary markers [19]. Infants who screen positive (potentially affected) are referred to one of five regional Newborn Screening Treatment Centres, which are based at pediatric tertiary care centres in the province. The Treatment Centre works with the infant’s primary health care provider to contact the parents and arrange for diagnostic evaluation, and is also responsible for on-going follow-up and management for affected children. The diagnostic evaluation typically includes plasma acylcarnitine profiling, urine organic acid analysis, and testing for mutations in ACADM [19]. Neonates are classified by the Treatment Centre and Newborn Screening Ontario medical staff review results. Infants are classified as true positive if they have a disease-associated genotype (e.g., homozygous for the c.985A > G mutation), and/or have persistent abnormal plasma acylcarnitines, and/or hexanoylglycine detected on urine organic acids analysis. Infants with normal metabolic profiles on diagnostic testing are defined as having received false positive screening results.

A primary comparison cohort included all children with negative newborn screening results for all disorders during the same time period. A secondary comparison cohort included 10 controls with negative screening results matched to each child with a false positive result for MCADD, based on sex, calendar year of birth, urban-rural status of the child’s residence, and an area-based indicator of socioeconomic status. The purpose of the matched comparison cohort was to address potential residual confounding by factors that may be associated with access to health services. Individuals were excluded from the study if they were ineligible for health care coverage at the time of birth or deceased within 24 h following birth (a bloodspot sample must be collected at > 24 h of age in Ontario to be considered satisfactory).

Newborn screening diagnostic confirmation data were securely linked to the provincial health care patient registry at the Institute for Clinical Evaluative Sciences, and then to administrative databases encompassing health service visits from April 1, 2006 through March 31, 2012. Physician encounters were identified using the OHIP Claims Database, which captures services provided by Ontario physicians who bill OHIP on a fee-for-service basis; and services provided by most other Ontario physicians who work in capitation payment models [22]. Emergency department (ED) visit data were retrieved from the Canadian Institute for Health Information’s National Ambulatory Care Reporting System, covering nearly all ED visits in Ontario [20]. Inpatient hospitalization data were obtained from the Canadian Institute for Health Information’s Discharge Abstract Database, covering all acute inpatient facilities in the province [21].

Potential confounding variables

Additional variables were ascertained from the hospitalization database at the time of birth (sex, birth weight, gestational age, season of birth), and Census/geographic data linked by the child’s postal code (socioeconomic status, urban-rural status). We grouped children into low (< 2500 g) and normal/high (≥ 2500 g) birth weight categories. We dichotomized gestational age to preterm (< 37 weeks) and term/post-term (≥ 37 weeks). Season of birth was categorized as January–April, May–August, or September–December.

A proxy measure of socioeconomic status was defined as the neighborhood-level income quintile, based on average household income data from the 2006 Canadian Census, linked to a child’s residential postal code at birth [23]. Neighborhoods were Census “dissemination areas”, with populations of approximately 400–700 persons; income quintiles were assigned across dissemination areas within larger regions [24]. We merged the two lowest and three highest quintiles to define lower and higher socioeconomic status. Urban-rural status of the child’s residence at birth was defined using the Rurality Index for Ontario, based on population size and density and on travel time to higher levels of hospital care [25]. We defined a rural community using a score of ≥ 40, the criterion used for rural physician eligibility in Ontario [26].

Utilization outcomes

We included each original health service encounter within the study period (physician visits, ED visits, and hospitalizations). If a child had multiple billed procedures within a single physician visit, these were considered as one visit. However, if a child saw multiple physicians on the same day, these were considered separate encounters. Each ED visit was a separate encounter as was each inpatient hospitalization.

Statistical analysis

Study datasets were linked using unique encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences; cell sizes < 6 were not reported due to privacy policies. Counts and percentages were calculated and chi-square tests used to examine bivariate associations between sociodemographic characteristics and cohort membership.

The number of physician visits, ED visits, and hospitalizations during the study period were summed for each child. The length of follow-up for each individual was the time elapsed between the date of birth and the earliest of 3 possible end points: the date of OHIP eligibility loss (mainly related to emigration from Ontario), the date of death, or the last date of follow-up for the study. Unadjusted visit rates and incidence rate ratios (IRR) were calculated to compare the false positive and screen negative cohorts.

Using the Vuong test as a criterion [27], we chose negative binomial regression modeling to compute IRRs for health services comparing the false positive with the screen negative cohorts while adjusting for confounders. Influential observations were identified [28, 29] and truncated to the 99th percentile for each service type. Models were stratified by age at the time of visit (< 1 year of age and ≥ 1 year of age). As a sensitivity analysis to address potential residual confounding by premature birth, we re-ran final models restricted to children with term births (≥ 37 weeks’ gestation). Finally, as a post-hoc sensitivity analysis, we re-ran the final model for physician visits excluding the first month of life, when some visits were likely related to resolving a positive screen as a false positive. This 1-month period was based on the clinical experience of metabolic physicians in Ontario. Analyses were performed using SAS® version 9.3 (SAS Institute, North Carolina, USA).

Results

Study population

Forty-three children had false positive newborn screening results for MCADD during the study period. The primary comparison cohort consisted of 545,355 children. The matched comparison cohort included 420 children identified as suitable matches for the false positive children. Children with false positive results for MCADD were more likely to be male, have a birth weight < 2500 g and have a gestational age < 37 weeks relative to the primary comparison group (Table 1). Follow-up time ranged from less than one month to approximately 6 years of age (mean and range: 49 months, < 1 to 67 months in the false positive cohort; 48 months, < 1 to 77 months in the primary comparison group).

Table 1 Geographic and sociodemographic characteristics of the study population
Full size table

Health care visit rates

Children with false positive newborn screening results for MCADD had 1939 recorded physician visits over the follow-up period, with an average unadjusted visit rate of 10.98 physician visits per child per year (Fig. 1). Children in the primary and secondary comparison groups had average rates of 8.44 and 9.00 physician visits per child per year respectively. Those with false positive results for MCADD had a total of 105 ED visits over the follow-up period with an average rate of 0.60 ED visits per child per year; those in the comparison cohorts had averages of 0.66 and 0.72 ED visits per child per year, respectively. Finally, children with false positive newborn screening results had a total of 27 inpatient hospitalizations over the follow-up period with an average rate of 0.15 hospitalizations per child per year. Those in the primary and secondary comparison groups had inpatient hospitalization rates of 0.06 and 0.08 stays per child per year, respectively.

Fig. 1
figure1

Unadjusted health service visit rates stratified by age at the time of visit (error bars show 95 % confidence intervals)

Full size image

Children in all 3 cohorts had the highest unadjusted rates of physician use, ED visits, and hospitalization rates during their first year of life (Fig. 1). In the first year of life, children with false positive newborn screening results for MCADD had an average of 26.1 physician visits, 1.0 ED visits, and 0.5 hospital admissions per child. These rates decreased to, on average, 6.3 physician visits, 0.5 ED visits, and 0.05 hospitalizations per child per year in subsequent years of age. In the first year of life, those in the primary comparison group had on average 14.7 physician visits, 0.8 ED visits, and 0.1 hospitalizations per child; these rates similarly decreased in subsequent years to an average of 6.3 physician visits, 0.6 ED visits, and 0.04 hospitalizations per child per year. Finally, in the first year of life, children in the matched comparison group had on average 18.0 physician visits, 0.9 ED visits, and 0.2 hospitalizations per child; these rates decreased in subsequent years to an average of 6.6 physician visits, 0.7 ED visits, and 0.05 hospitalizations per child per year.

Incidence rate ratios for individual health care service types

In the first year of life, after adjusting for potential confounding factors as previously described, children with false positive results for MCADD had a statistically significant higher rate of physician visits (IRR: 1.42 [95 % CI: 1.21–1.67]) and inpatient hospitalizations (IRR: 2.32 [95 % CI: 1.22–4.34]) relative to the primary comparison group; there was no significant difference in the frequency of ED visits (IRR: 1.27 [95 % CI: 0.80–2.03]) (Table 2). There were no statistically significant differences for any of the three service types in the false positive versus primary comparison cohort among children older than 1 year of age. Results were similar for the false positive versus matched comparison cohort, with the exception of ED visits during the first year of life, where children with false positive results had a relatively lower frequency of ED visits (IRR: 0.81 [95 % CI: 0.52–1.27]) (Table 3); this difference was not statistically significant.

Table 2 Stratified adjusted models (< 1 year old and ≥ 1 year old) showing incidence rate ratios for the three service types, comparing the false positive cohort with the primary (unmatched) comparison cohort
Full size table
Table 3 Stratified adjusted models (< 1 year old and ≥ 1 year old) showing incidence rate ratios for the three service types (matched comparison group)
Full size table

When the age-stratified models were restricted to children with term births (Table 4), the results were similar to those reported for all births (Table 2). In the first year of life, term children with false positive screening results for MCADD had a statistically significant higher rate of physician visits (IRR: 1.35 [95 % CI: 1.13–1.63]) compared to term children with negative screening results. While there was no statistically significant difference in hospitalization rates in the two cohorts among term children less than 1 year of age, the estimated IRR (IRR: 2.32 [95 % CI: 0.87–5.65) was virtually identical to the IRR from the model for all births (IRR: 2.32 [95 %: 1.22–4.34]). No statistically significant differences were observed for health services use among term children aged one year and older. Finally, when we re-examined physician visits over the first year of life in the entire cohort to exclude the first month of life, children with false positive results still experienced higher rates of physician care relative to those in the primary comparison group (IRR: 1.31 [95%CI: 1.11–1.57]).

Table 4 Stratified adjusted models (< 1 year old and ≥ 1 year old) showing incidence rate ratios for the three service types for term infants only, false positive cohort versus primary (unmatched) comparison cohort
Full size table

Discussion

In this population-based study, after adjustment for potential confounders, children with false positive newborn screening results for MCADD experienced a statistically significant higher frequency of physician visits and hospitalizations, but not ED visits, as compared to screen negative comparison groups in the first year of life. Our findings are consistent with a Beijing study that identified a higher rate of parent-reported hospitalizations in the first 6 months of life among children with false positive versus negative newborn screening results for a range of metabolic disorders [7]. However, an American study, also focused on metabolic disorders, found no statistically significant differences in parent-reported health care use among infants with false positive versus negative screening results [3–5]. The only previous study relying on administrative records, rather than parent reports, involved a US Medicaid population and focused on false positive results for metabolic, endocrine, or hematologic disorders [10]. In that study the authors identified no difference in health care use among children with false positive versus negative screening results, with the exception of preterm infants, among whom false positive results were associated with a higher rate of acute outpatient visits [10]. However, the authors hypothesized that the parental psychosocial response may differ for different screened diseases [10]. To our knowledge, ours is the first disease-specific study to compare health services use in these populations.

While the psychosocial consequences of a false positive newborn screening test are short-term for the majority of parents, studies suggest that a small proportion continue to experience anxiety following diagnostic testing [30, 31]. Such anxiety, or misunderstanding of the diagnostic result, could alter parental perceptions of a child’s vulnerability to illness, similar to the well-documented phenomenon of the “vulnerable child syndrome” [32]. As a result, such families may seek health care at an increased frequency for their child. This is one potential explanation for our findings with respect to physician visits under 1 year of age. However, it is unlikely to explain the increased hospitalizations under one year of age in the false positive versus comparison group, particularly in the absence of a similar increase in ED visits. Given the rarity of MCADD and likely lack of experience with the disorder for most physicians, physician perceptions may also have played a role. For example, this may have resulted in a greater likelihood of hospital admission among infants with false positive results presenting to an ED, particularly if accompanied by parents experiencing anxiety or confusion about the nature of the result.

Another potential explanation for our findings that we considered is that the increase in physician visits during the first year of life might reflect supplementary health service visits related to confirmatory diagnostic testing for the positive newborn screening result. However, after excluding visits during the first month of life, when the vast majority of diagnostic care would occur for children with false positive results in Ontario, that cohort still experienced a higher rate of physician visits in the entire first year of life relative to screen-negative controls.

A further possible explanation for the higher rate of the use of certain health services in the first year of life in children with false positive results is a residual confounding effect of premature birth. We adjusted for gestational age and birth weight in our multivariable analyses, since children with false positive results for MCADD are more likely to be of lower gestation and birth weight [10-12]. However, due to our small sample size, we dichotomized both birth weight and gestational age rather than using smaller categories as has been recommended [33, 34]. To investigate a role for residual confounding by gestational age, we restricted the analysis to children with gestational age ≥ 37 weeks. In that analysis, the results for physician visits were similar to those in the main analysis and the results for hospitalizations yielded the same effect size; this suggests that residual confounding by gestational age does not explain our findings.

Finally, it is possible that physiological differences aside from gestational age and birth weight may be associated with the biochemical markers used in the screening test and may influence health care use during the first year of life. For example, we did not have information about underlying illnesses aside from those that are part of the newborn screening panel. This potential explanation for our findings is supported by a study that identified a higher prevalence of low birth weight and/or time spent in a neonatal intensive care unit in infants with elevated screening markers for MCADD [35]. A limitation of using health care administrative datasets is the lack of both clinical detail and family-reported information. As a result, we were unable to directly investigate the role of clinical characteristics such as underlying illness and, similarly, we could not directly study parental or physician perceptions of infants’ health. Further research is needed to further explore these potential explanations. Should such research confirm a psychosocial effect leading to higher health service use, our findings support the use of strategies shown to mitigate parental anxiety in the face of false positive findings, including effective education and provider communication during confirmatory follow-up [30, 36].

Conclusions

Infants with false positive newborn screening results for MCADD may experience higher health care use in the first year of life as a result of parental and physician perceptions of their health status or unmeasured confounding. More research is needed to investigate competing explanations and to directly study the psychosocial impact of false positive findings. Understanding the impact of false positive newborn screening results can help to inform newborn screening programs, and health care providers involved in such programs, in designing support and education to benefit families of children receiving positive results. Specifically, if some parents or non-metabolic specialist health care providers have misperceptions about the health of children with false positive newborn screening results, there may be a need for further parental and provider education about the clinically benign status of such results; and for additional counselling services for parents who remain concerned. This is particularly important as additional disorders are added to expanded screening panels, leading to important clinical benefits for children with rare treatable disorders but also a higher frequency of false positive findings.

References

  1. 1.

    Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39(3):171–87.

    Article  PubMed  Google Scholar 

  2. 2.

    Centers for Disease Control and Prevention (CDC). Ten great public health achievements--United States, 2001–2010. MMWR Morb Mortal Wkly Rep. 2011;60(19):619–23.

    Google Scholar 

  3. 3.

    Lipstein EA, Perrin JM, Waisbren SE, Prosser LA. Impact of false-positive newborn metabolic screening results on early health care utilization. Genet Med. 2009;11(10):716–21.

    PubMed Central  Article  PubMed  Google Scholar 

  4. 4.

    Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics. 2006;117(6):1915–21.

    Article  PubMed  Google Scholar 

  5. 5.

    Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA. 2003;290(19):2564–72.

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Wilcken B. Screening for disease in the newborn: the evidence base for blood-spot screening. Pathology. 2012;44(2):73–9.

    Article  PubMed  Google Scholar 

  7. 7.

    Tu WJ, He J, Chen H, Shi XD, Li Y. Psychological effects of false-positive results in expanded newborn screening in China. PLoS One. 2012;7(4), e36235.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  8. 8.

    Tluczek A, Orland KM, Cavanagh L. Psychosocial consequences of false-positive newborn screens for cystic fibrosis. Qual Health Res. 2011;21(2):174–86.

    PubMed Central  Article  PubMed  Google Scholar 

  9. 9.

    Morrison DR, Clayton EW. False positive newborn screening results are not always benign. Public Health Genomics. 2011;14(3):173–7.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Tarini BA, Clark SJ, Pilli S, Dombkowski KJ, Korzeniewski SJ, Gebremariam A, et al. False-positive newborn screening result and future health care use in a state Medicaid cohort. Pediatrics. 2011;128(4):715–22.

    PubMed Central  Article  PubMed  Google Scholar 

  11. 11.

    McCandless SE, Chandrasekar R, Linard S, Kikano S, Rice L. Sequencing from dried blood spots in infants with “false positive” newborn screen for MCAD deficiency. Mol Genet Metab. 2013;108(1):51–5.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  12. 12.

    Slaughter JL, Meinzen-Derr J, Rose SR, Leslie ND, Chandrasekar R, Linard SM, et al. The effects of gestational age and birth weight on false-positive newborn-screening rates. Pediatrics. 2010;126(5):910–6.

    Article  PubMed  Google Scholar 

  13. 13.

    Rhead WJ. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: A global perspective. J Inherit Metab Dis. 2006;29(2–3):370–7.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med. 2006;8(4):205–12.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Ziadeh R, Hoffman EP, Finegold DN, Hoop RC, Brackett JC, Strauss AW, et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res. 1995;37(5):675–8.

    Article  CAS  PubMed  Google Scholar 

  16. 16.

    Wang SS, Fernhoff PM, Hannon WH, Khoury MJ. Medium chain acyl-CoA dehydrogenase deficiency human genome epidemiology review. Genet Med. 1999;1(7):332–9.

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Andresen BS, Dobrowolski SF, O’Reilly L, Muenzer J, McCandless SE, Frazier DM, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet. 2001;68(6):1408–18.

  18. 18.

    Leonard JV, Dezateux C. Newborn screening for inborn errors of metabolism: principles, policies and weighing the evidence. Paediatr Child Health. 2011;21(2):56–60.

    Article  Google Scholar 

  19. 19.

    Kennedy S, Potter BK, Wilson K, Fisher L, Geraghty M, Milburn J, et al. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by Newborn Screening Ontario. BMC Pediatr. 2010;10:82.

  20. 20.

    Canadian Institute for Health Information. National Ambulatory Care Reporting System data quality documentation, current-year information, 2011–2012. Toronto: Canadian Institute for Health Information; 2012.

  21. 21.

    Canadian Institute for Health Information. Discharge Abstract Database data quality documentation, current-year information, 2011–2012. Toronto: Canadian Institute for Health Information; 2012.

  22. 22.

    Collier R. Shift toward capitation in Ontario. CMAJ. 2009;181(10):668–9.

    PubMed Central  Article  PubMed  Google Scholar 

  23. 23.

    Canada S. 2006 census dictionary. Ontario: Ottawa; 2007.

    Google Scholar 

  24. 24.

    Wang C, Guttmann A, To T, Dick PT. Neighborhood income and health outcomes in infants: how do those with complex chronic conditions fare? Arch Pediatr Adolesc Med. 2009;163(7):608–15.

    Article  PubMed  Google Scholar 

  25. 25.

    Kralj B. Measuring rurality - RIO2008 BASIC: methodology and results. Ottawa: Ontario Medical Association; 2009. http://www.oma.org/Resources/Documents/2008RIO-FullTechnicalPaper.pdf. Accessed October 9, 2015.

  26. 26.

    Ontario Ministry of Health and Long-term Care. Rural Physician Eligibility Requirements. Toronto: Ontario Ministry of Health and Long-term Care; 2013. Available from: www.healthforceontario.ca. Accessed October 9, 2015.

  27. 27.

    Vuong QH. Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica. 1989;57(2):307–33.

    Article  Google Scholar 

  28. 28.

    Bollen KA, Jackman RW. Regression diagnostics: an expository treatment of outliers and influential cases. Sociol Methods Res. 1985;13(4):510–42.

    Article  Google Scholar 

  29. 29.

    Belsley D, Kuh E, Welsch RE. Regression diagnostics: identifying influential data and sources of collinearity. Hoboken: Wiley-Interscience; 2005.

    Google Scholar 

  30. 30.

    Wildner M. Health economic issues of screening programmes. Eur J Pediatr. 2003;162(Suppl):S5–7.

    Article  PubMed  Google Scholar 

  31. 31.

    Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. Clin Biochem. 2007;40(3–4):235–41.

    Article  CAS  PubMed  Google Scholar 

  32. 32.

    Kokotos F. The vulnerable child syndrome. Pediatr Rev. 2009;30:193–4.

    Article  PubMed  Google Scholar 

  33. 33.

    World Health Organization. International statistical classification of diseases and related health problems. 10th ed. Geneva: WHO; 2010.

    Google Scholar 

  34. 34.

    Statistics Canada. Data quality, concepts and methodology: definitions. Ontario: Ottawa; 2013.

  35. 35.

    Lehotay DC, LePage J, Thompson JR, Rockman-Greenberg C. Blood acylcarnitine levels in normal newborns and heterozygotes for medium-chain acyl-CoA dehydrogenase deficiency: A relationship between genotype and biochemical phenotype? J Inherit Metab Dis. 2004;27(1):81–8.

    Article  CAS  PubMed  Google Scholar 

  36. 36.

    Hamers FF, Rumeau-Pichon C. Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France. BMC Pediatr. 2012;12:60.

Download references

Acknowledgements

We gratefully acknowledge Robin Ducharme for her assistance in preparing the datasets for this study. This study was Funded through a Canadian Institutes of Health Research (CIHR) Emerging Team Grant (TR3-119195). Maria Karaceper received a graduate scholarship through a charitable donation to the Children’s Hospital of Eastern Ontario. This study was performed at the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The opinions, results and conclusions reported in this paper are those of the authors and are independent from all funding sources. Study sponsors had no role in the following: (1) study design; (2) the collection, analysis, and interpretation of data; (3) the writing of the report; and (4) the decision to submit the paper for publication.

Author information

Affiliations

  1. School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, 451 Smyth Rd, Ottawa, ON, K1H 8 M5, Canada

    Maria D. Karaceper, Doug Coyle, Brenda J. Wilson & Beth K. Potter

  2. Newborn Screening Ontario, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada

    Pranesh Chakraborty & Christine Davies

  3. Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

    Kumanan Wilson & Steven Hawken

  4. Department of Pediatrics, Division of Clinical & Metabolic Genetics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

    Jonathan B. Kronick & Annette Feigenbaum

  5. Manitoba Centre for Health Policy, Department of Community Health Sciences, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

    Marni Brownell

  6. Departments of Obstetrics & Gynecology and Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada

    Linda Dodds

  7. Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada

    Deshayne B. Fell

  8. Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, Georgia, USA

    Scott D. Grosse

  9. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada

    Astrid Guttmann

  10. Department of Pediatrics, Division of Paediatric Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

    Astrid Guttmann

  11. Medical Genetics, CHU Sainte-Justine and Department of Pediatrics, Université de Montréal, Montréal, Québec, Canada

    Anne-Marie Laberge

  12. Department of Paediatrics and Child Health, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

    Aizeddin Mhanni & Cheryl Rockman-Greenberg

  13. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

    Astrid Guttmann & Fiona A. Miller

  14. Montreal Children’s Hospital, McGill University, Montreal, Quebec, Canada

    John J. Mitchell & Meranda Nakhla

  15. Genetics, Metabolism and Pediatrics, London Health Sciences Centre, Western University, London, Ontario, Canada

    Chitra Prasad

  16. Department of Paediatrics, Section of Clinical Genetics, Alberta Children’s Hospital, Calgary, Alberta, Canada

    Rebecca Sparkes

  17. Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

    Kumanan Wilson

Authors
  1. Maria D. Karaceper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pranesh Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Doug Coyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kumanan Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jonathan B. Kronick
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steven Hawken
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christine Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marni Brownell
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Linda Dodds
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Annette Feigenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Deshayne B. Fell
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Scott D. Grosse
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Astrid Guttmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Anne-Marie Laberge
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Aizeddin Mhanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Fiona A. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. John J. Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Meranda Nakhla
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Chitra Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Cheryl Rockman-Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Rebecca Sparkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Brenda J. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Beth K. Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Canadian Inherited Metabolic Diseases Research Network

Corresponding author

Correspondence to Beth K. Potter.

Additional information

Competing interests

A Guttmann receives salary support from a CIHR Applied Chair in Child Health Services Research. M Brownell receives salary support from the Government of Manitoba through the Manitoba Centre for Health Policy Population-Based Child Health Research Award. The following authors declare no competing interests: M Brownell, C Davies, P Chakraborty, D Coyle, L Dodds, A Feigenbaum, DB Fell, S Grosse, A Guttmann, S Hawken, MD Karaceper, JB Kronick, AM Laberge, AA Mhanni, FA Miller, JJ Mitchell, M Nakhla, C Prasad, BK Potter, C Rockman-Greenberg, R Sparkes, B Wilson, K Wilson.

Authors’ contributions

MDK conceptualized and designed the study, analyzed and interpreted the data, drafted the manuscript, and approved the final manuscript as submitted. BKP conceptualized, designed and supervised the study, analyzed and interpreted the data, drafted the manuscript, and approved the final manuscript as submitted. PC, DC, and KW conceptualized, designed and supervised the study, interpreted the findings, revised the manuscript for important intellectual content, and approved the final manuscript as submitted. JBK conceptualized and designed the study, interpreted the findings, revised the manuscript for important intellectual content, and approved the final manuscript as sbutmitted. SH and CD acquired and prepared the data, advised on the analysis of the data, interpreted the findings, revised the manuscript for important intellectual content, and approved the final manuscript as submitted. MB, LD, AF, DBF, SDG, AG, AML, AM, FAM, JJM, MN, CP, CRG, RS, and BJW conceptualized the study, interpreted the findings, revised the manuscript for important intellectual content, and approved the final manuscript as submitted. All authors read and approved the final manuscript.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Karaceper, M.D., Chakraborty, P., Coyle, D. et al. The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Orphanet J Rare Dis 11, 12 (2016). https://doi.org/10.1186/s13023-016-0391-5

Download citation

Keywords

  • Neonatal screening
  • Metabolic diseases
  • Health services utilization

Orphanet Journal of Rare Diseases

ISSN: 1750-1172

\